We are live on ! Find out more
HQL

abrdn Life Sciences Investors

61 hedge funds and large institutions have $50M invested in abrdn Life Sciences Investors in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

92% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 13

11% more funds holding

Funds holding: 5561 (+6)

0.62% more ownership

Funds ownership: 13.91%14.54% (+0.62%)

6% less capital invested

Capital invested by funds: $53.3M → $50M (-$3.29M)

Holders
61
Holders Change
+6
Holders Change %
+10.91%
% of All Funds
1.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
25
Reduced
13
Closed
3
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q3 2019 in Review

61 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q3 2019, worth a combined $50M — down 6.2% from $53.3M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new HQL positions and 3 closed out — a net gain of 6 holders — while 25 added to existing stakes and 13 trimmed.

The largest buyer was Wolverine Asset Management, adding an estimated $705K. The largest seller was Raymond James & Associates, cutting an estimated $796K.

  • 61 institutional investors held abrdn Life Sciences Investors (HQL) as of Q3 2019, up from 55 in Q2 2019.
  • Funds reported $50M of abrdn Life Sciences Investors stock for Q3 2019, down 6.2% quarter-over-quarter.
  • 9 funds opened new abrdn Life Sciences Investors positions in Q3 2019 and 3 closed out, a net change of +6 holders.
  • The largest abrdn Life Sciences Investors buyer in Q3 2019 was Wolverine Asset Management, an estimated $705K added.
  • The largest abrdn Life Sciences Investors seller in Q3 2019 was Raymond James & Associates, an estimated $796K sold.

Based on aggregated 13F filings for Q3 2019.